Tuesday, September 6, 2016

News: VEXIM Announces the Registration of Its Products SpineJack® and Masterflow™ For the Treatment of Vertebral Fractures in Australia

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:
Image result for spinejack vexim
VEXIM (Paris: ALVXM) (FR0011072602 – ALVXM / PEA‐PME), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces it has received the regulatory approval from the Therapeutic Goods Administration (TGA) in order to commercialize the SpineJack® and the cement delivery system MasterflowTM in Australia.
This success opens a new market opportunity for VEXIM in Australia which represents a potential market of €30 million in the treatment of vertebral compression fractures according to VEXIM’s estimations.
The company keeps expanding its international presence whilst preparing new products’ development.
Vincent Gardès, VEXIM’s CEO, concludes: “This registration will enable us to have a substantial increase of our global activities. The company considers launching the exportation in Australia by the end of 2016.”
***
Image result for spinejack veximAbout VEXIM, the innovative back microsurgery specialist - Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital1 and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the MasterflowTM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 62 employees, including its own sales teams in Europe and a network of international distributors.VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com
SpineJack® 2, a revolutionary implant for treating Vertebral FracturesThe revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.
MasterflowTM 2, a high-performance orthopedic cement delivery systemThe MasterflowTM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack®, the MasterflowTM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The MasterflowTM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.
1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
2 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.
VEXIM
Vincent Gardès, Tél. : +33 5 61 48 48 38 | CEO - investisseur@vexim.com
or

PRESS - ALIZE RP | Caroline Carmagnol / Wendy Rigal | Tél. : +33 1 44 54 36 66 | Tél. : +33 6 48 82 18 94 | vexim@alizerp.com

Published at streetinsider.com

No comments:

Post a Comment